TaiMed Biologics Reports Accelerated Enrollment for HIV Long-Acting Combo TMB-365/380

TaiMed Biologics (中裕新藥) announced today that its Phase 2b trial for the long-acting HIV antibody combination TMB-365/380 is ahead of schedule. The therapy is gaining significant traction with international potential partners due to its unique "No-Screening" advantage.